MaxorPlus is now offering Humira biosimilar options with select standard formularies. Humira is a prescription injection used to treat rheumatoid arthritis, juvenile arthritis, Crohn’s disease, ankylosing spondylitis, and other autoimmune disorders. There is significant potential in biosimilars to address high specialty costs for our clients.
Our biosimilar options include:
- Cyltezo (adalimumab-adbm) (Boehringer Ingelheim), the first interchangeable biosimilar with Humira, low concentration formulation
- Adalimumab-adaz (Sandoz), high-concentration formulation (unbranded)
- Hyrimoz (Sandoz), high-concentration formulation
- Amjevita
- Select formulations
These changes will bring meaningful choice and savings opportunity to patients and prescribers. MaxorPlus will continue to monitor this class as additional Humira biosimilar products come to market and provide updated guidance as appropriate.
